Science in the UK − whereto now?  by Bustin, Stephen
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cience  in  the  UK  −  whereto  now?Humour in Britain is appreciated for its quirkiness and ironic
elf-deprecation and can sometimes seem bafﬂing to the outside
orld. The outcome of the recent United Kingdom referendum
here a narrow-ish majority voted to leave the European Union
s certainly perplexing to most onlookers and, if its consequences
ere not so far-reaching, might be laughed off as an illustration of
uch absurd humour. One of the most farcical aspects of the vote
s that no one has any idea what “Brexit” actually means no matter
ow often the ignorant slogan “Brexit means Brexit” is repeated.
owever, an immediate consequence is that the uncertainties cre-
ted by the vote, and its potential impact on science, continues
o be the subject of widespread, anxious and incredulous debate
mongst scientists in the UK and between their many friends and
ollaborators in the world-wide scientiﬁc community. Objectively,
t is difﬁcult to discern a single coherent argument that can be made
or Brexit, and there can be little doubt that the human, societal and
nancial implications of this needless debacle could be both wide
eaching and damaging.
UK science is highly competitive and EU and UK researchers
ave become linked in an extensive collaborative network that has
een of immense beneﬁt to UK (and EU) science, with levels of
nter-country collaborations within the EU (13%) similar to those
f inter-state collaborations within the USA (16%) [1]. Together
ith scientists from other EU countries, British scientists com-
rise around 22% of researchers worldwide, way ahead of the USA
17%) [2]. European researchers are also productive as measured
y publications and author around 34% of the world’s research out-
uts, with the USA trailing at 23% [1]. Between 2005 and 2014,
K researcher output rose from 70,201 to 87,948, second only to
ermany (73,573–91,631) and way ahead of next-placed France
52,476–65,086). Indeed, for publications in biological and medi-
al sciences, British authors are the most proliﬁc by far (Fig. 1). UK
nstitutions have been awarded by far the most research grants
y the European Research Council [3], which funds individual
rojects solely on the basis of their scientiﬁc excellence and so
elps researchers bypass what is sometimes perceived as a less
bjective distribution of monies from national research councils.
etween 2007 and 2015, the UK accounted for 639/3056 grants,
ith next-placed Germany obtaining 440. The UK has been simi-
arly successful with the EU’s Horizon 2020 programme, with nearly
2% of the applications received under the ﬁrst 100 calls accounting
or 15% of the available funding [4]. The Royal Society reckons from
ata released by the UK Ofﬁce of National Statistics that between
007 and 2013 the UK received a net amount of D 2.9 billion in direct
ttp://dx.doi.org/10.1016/j.bdq.2016.08.001
214-7535/© 2016 The Author(s). Published by Elsevier GmbH. This is an open access ar
d/4.0/).EU funding for research, development and innovation activities
[5].
EU funding has become essential to British science, since it is
augmenting UK-based research at a time when British government
funding is decreasing. Undoubtedly there are many ways of pre-
senting the available ﬁnancial data, but a straightforward reading
of the likely unbiased UNESCO Science report reveals that the ratio
of UK gross domestic expenditure on research and development
(GRED) to GDP declined from 1.75 in 2009–1.63 in 2013, at a time
when the average ratio for all 28 EU countries rose from 1.94 to 2.02
[1]. The UK government’s own ﬁgures show that whilst in 2014 it
spent £11.0 billion on science, engineering and technology, a nom-
inal increase of 0.4% compared with 2013, once inﬂation is taken
into account this represented a 1.0% decrease. Furthermore, the
contribution of the UK Research Councils, which amounted to 31%
of all expenditure in this area, decreased by 3% in current prices
compared with 2013 [6].
The ﬁnancial argument for the UK remaining within the EU is
clearly overwhelming, but is but one aspect of the importance of
membership of the EU for British and European science. The contin-
ued free movement of people is similarly signiﬁcant and is vital for
creating global network of contacts, helps stimulate innovation and
the inherent exposure to different cultures and viewpoints helps
make this a better world. The English-speaking UK with its close
links to the USA is a very attractive destination for experienced aca-
demics, students and post-doctoral workers alike, who contribute
not just their talents and enrich society with their cultural diver-
sity but also make a signiﬁcant economic and ﬁnancial contribution
to the UK in general and universities in particular. It is particu-
larly ironical (more British humour?) that the UK government sees
tougher regulation on universities as an appropriate way  of reduc-
ing net immigration and argues that universities should develop
sustainable funding models that are not so dependent on interna-
tional students [7]. How ingenious then to threaten the potential for
EU funding, which goes mainly to scientists working at universities
and research institutions, by withdrawing from the EU. Further-
more, most students return to their home countries and carry
back with them the impressions, values and principles they have
acquired in the UK and become part of the international collabo-
rative network that has become the hallmark of modern science.
Of course, the British pharmaceutical and biotechnology indus-
tries and many small and medium enterprises innovating scientiﬁc
instrumentation, medical devices and diagnostic kits also make an
essential contribution to overall scientiﬁc output and advances and
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
A2 Editorial / Biomolecular Detection and Quantiﬁcation 9 (2016) A1–A4
ntists
b
p
p
m
i
a
I
t
9
i
t
i
T
m
a
l
d
d
a
c
o
i
c
s
r
b
b
t
b
v
o
c
b
t
b
a
eFig. 1. Scientiﬁc publications authored by scie
eneﬁt from trans-national funding and the free movement of peo-
le and services.
An authoritative and comprehensive examination of the Euro-
ean publics’ attitude to science and technology suggest that
ost people understand the fundamental importance of these
ssues [8]. The increasing importance of collaborative research is
cknowledged by 74% of respondents, with only 5% disagreeing.
nterestingly the UK was second from bottom amongst all EU coun-
ries, although a healthy 64% agreed with that statement and only
% disagreed. Most people also believe that collaborative research
s in the national (66% vs 10%) and society’s (69% vs 9%) interest and
hat it makes science more creative and efﬁcient (62% vs 9%). Again
t is notable that UK respondents are not as convinced (51% vs 14%).
he public also understand that it is normal for EU researchers to
ove from one member state to another to further their career (59%
gree, 11% disagree), but it is again noticeable that the UK public are
ess likely to agree with this requisite: only 46% agree, whereas 18%
isagree). Finally, 72% of Europeans believe, compared to 7% that
o not, that it is important to create European research centres that
llow researchers from all EU countries to collaborate at one physi-
al location. Again the UK response is somewhat less positive, with
nly 61% of that opinion, compared to 11% that disagree.
One of the most notable features of the referendum campaign
n the UK was the reliably ill-informed and coarse standard of dis-
ourse, which gave rise to many dispiriting comments from both
ides of the divide. The true consequences of leaving the EU were
arely made clear in a manner that could be objectively deliberated
y the electorate; instead arguments were generally characterised
y emotion, fabrication and misrepresentation of facts. For scien-
ists, one of the most foolish assertions surely was the declaration
y the then justice secretary Michael Gove, a graduate of the Uni-
ersity of Oxford, that “people in this country have had enough
f experts”. Whilst this comment appeared to be directed speciﬁ-
ally at economists, it nevertheless represents a shocking attitude
y a supposedly educated member of the establishment. However,
here is a wider context to consider, since the media regularly
roadcasts scientiﬁc and medical discoveries, and scientists appear
s experts to explain one ﬁnding or other, frequently offering differ-
nt opinions. Hence comments such as the one by Mr  Gove should located in the four largest EU member states.
make us think and re-evaluate our own  role as scientists and how
the wider community perceives our role and expertise.
The usual deﬁnition of an expert is someone who is knowl-
edgeable about or skilful in a particular area. An expert’s role
with regards to communication is to use that expertise to provide
impartial, comprehensive and relevant research- and fact-based
evidence. To be credible, the expert must convey sincerity and
integrity and if the communication is done competently, sensitively
and appropriately, that evidence should provide the information a
target audience requires to act, or in the case of the UK referendum,
vote rationally. Ultimately, an expert’s value depends on whether
the public can trust that expert’s testimony. Trust is precious and
must be earned, and there have been several reasons why some
people might be mistrustful of scientists. One of the most egre-
gious instances of how dubious science affects public wellbeing is
provided by the controversy surrounding the link between of the
measles mumps  and rubella vaccine and autism [9]. Despite numer-
ous studies refuting any such link [10–14] and despite judgements
by the US federal vaccine injury compensation court upheld on
appeal [15], many members of the public remain unconvinced that
there is no connection between the two [16–18]. Other examples
include serious incidents biosafety incidents, which have occurred
in laboratories operated by the Centers for Disease Control and
Prevention (CDC) [19,20] and there are frequent reports of safety
violations and accidents at research facilities around the world. In
the UK a Guardian newspaper investigation uncovered over 100
accidents or near-misses at the high-security labs that handle the
most dangerous viruses and bacteria [21]. Such events must be han-
dled in a transparent, candid and respectful manner if they are not
to damage people’s trust in science and scientists.
In any event, the public’s opinion of science and scientists is
not straightforward. Any survey needs to be taken with a pinch of
salt these days, but the 2010 European Commission’s report on sci-
ence and technology paints a broadly positive picture of the general
publics’ perception, albeit with a few worrying tendencies. There is
a broad awareness of science, with 79% of Europeans either very or
moderately interested in new scientiﬁc discoveries and 61% feeling
either well or moderately well informed about them [8]. They are
also optimistic about the effects of science and technology, with 75%
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xpecting science and technology to provide more opportunities
or future generations, although 57% feel that scientists should put
ore effort into informing the public about these changes. Encour-
gingly, a majority (55%) of Europeans sees the need for a public
ialogue when decisions about new developments in science and
echnology are made [22]). However, 62% feel that science and tech-
ology can sometimes damage people’s moral sense and that 53%
gree with the statement that, because of their knowledge, scien-
ists “have a power that makes them dangerous”. The jury remain
ut on how all of this affects the public’s trust: 58% of Europeans
hink that the increasing dependence on funding from industry
eans that scientists can no longer be trusted to tell the truth about
ontroversial scientiﬁc and technological issues. Interestingly, 70%
f respondents in the scientiﬁc powerhouse Germany 70% agreed
ith that statement. Perhaps there is a link to the perception of
0% of respondents who believe that private funding of scientiﬁc
nd technological research limits the ability to understand things
ully. Conversely, in the UK scientists are a trusted profession, with
he two most recent Ipsos Mori veracity indices suggesting that 83%
2014) [23] or 79% (2015) [24] of the UK population trusts scientists
o tell the truth.
So what are we to do? Most scientists (85%) see the public’s
ack of knowledge about science as a major problem and 76% also
omplain about the media’s lack of distinction between sound sci-
nce and unscientiﬁc twaddle [25]. I strongly believe that one of
he lessons of the Brexit debacle is that scientists must become far
ore proactive in their involvement with and inﬂuence of poli-
ics. We  must accept that we need to engage in an active role with
he general public and demonstrate the signiﬁcance and beneﬁts
f our research, perhaps by joining political parties and shap-
ng policies right from the start. Historically, scientists believe in
ransparent, respectful and rational debate that tolerates and even
ncourages different opinions. We  are used to developing hypothe-
es, searching for factual evidence and modifying our hypotheses
f our experimental facts change, all in a search for truth. Few sci-
ntists, and certainly not those in academic posts, are motivated
y avarice, many, especially in less democratic countries, continue
o be examples of moral courage and most have a sincere social
onscience, sense of solidarity and are colour-blind. If we  really are
ntering a post-truth world that seems to be characterised by nar-
icissm, material greed, lack of moral courage and unwillingness
r inability to stand up for principles, I would argue that scien-
ists should act as beacons for pluralism, social justice, tolerance
nd reﬂective thought. Of course, rational debate and facts may
ot be sufﬁcient to convince an audience that has an emotional
ttachment to its views. Although scientists know that a question-
ng attitude is preferable to a dogmatic approach, most people are
onfused by scientiﬁc debate where several, sometimes contradic-
ory, opinions are discussed and where there may  be more than one
orrect answer. We  need to acknowledge this; but we also need to
nject some passion into our arguments, especially as there is plenty
o be passionate about: investment in science is a positive thing and
s essential for prosperity, it beneﬁts society, provides employment,
mproves health, brings people and cultures together, is generally
 force for good and, above all, science is exciting.
With regards to Brexit, for all its faults, the EU has nourished
hese values, especially with its drive towards funding excellence,
ncouraging the exchange of people and focussing on topics that
ndividual nation states tended to neglect. This should be an incen-
ive for us to “take back control” and not let politicians, journalists
nd other special interest groups destroy our precious network
f friends, collaborators, institutions and openness we have built
p over the past 40 years. There are many issues that must be
ackled and we must not be afraid to discuss these openly and
ith the greatest possible transparency. These include the seri-
us problems associated with inefﬁciency, lack of reproducibility
[ Quantiﬁcation 9 (2016) A1–A4 A3
and mistaken research priorities of biomedical research [26–31],
laboratory errors [32,33] and other issues highlighted in numer-
ous publications [34–40]. We  might also want to consider speaking
up against the challenges associated with the politicians’ love for
ludicrous quality metrics, the publish-or-perish culture that fos-
ters the publication of poor research, the associated inadequacy
of the peer review system and the increasing focus on translation
research at the cost of creative exploration. None of these issues
can be addressed unless we  are willing to engage with the many
interests that have driven these developments, some of which
are self-inﬂicted and self-perpetuating. But involve ourselves we
must, otherwise we cannot complain if others make vital decisions
against our judgements and interests that might jeopardise our
futures.
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